Elizabeth Lightbody, Associate Director of Clinical Development at Adela, shared a post on LinkedIn:
“Happy to share Adela’s latest clinical validation study, in collaboration with Princess Margaret Cancer Centre and University Health Network, has been published in npj Precision Oncology:
‘Clinical validation of a tissue-agnostic, genome-wide methylome enrichment assay to monitor response to pembrolizumab’.
We performed a blinded analysis of samples from INSPIRE, a phase II trial evaluating pembrolizumab across multiple advanced solid tumors, and demonstrated that a decrease in ctDNA from baseline to pre-cycle 3 was significantly associated with higher objective response and clinical benefit rates, as well as longer PFS and OS.
Overall, our genome-wide methylome enrichment platform introduces clinically meaningful new capabilities for response monitoring:
- No tumor tissue required – expands access to patients without adequate tissue
- No patient-specific mutation profiling required – supports faster clinical deployment
- Enables early response assessment – particularly valuable in immunotherapy, where early changes may guide treatment decisions and optimize therapy.”
Title: Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Authors: Eric Y. Stutheit-Zhao, Yongqi Zhong, Collin A. Melton, Elizabeth D. Lightbody, Michael A. Hinterberg, Yarong Wang, Owen Hall, Eduardo V. Sosa, Jeremy B. Provance, Junjun Zhang, Abel Licon, Zhihui Amy Liu, Albiruni R. Abdul Razak, Anna Spreafico, Philippe L. Bedard, Aaron R. Hansen, Stephanie Lheureux, Pamela S. Ohashi, Alan Williams, Scott V. Bratman, Brian A. Allen, Jing Zhang, Daniel D. De Carvalho, Anne-Renee Hartman, Lillian L. Siu, Enrique Sanz-Garcia
Read The Full Article
Other articles about ctDNA on OncoDaily.